The FDA reexamines asbestos testing for talc powders and cosmetics; elderly patients with HIV have high polypharmacy use; the government issues an emergency use authorization for a coronavirus diagnostic.
On Tuesday, for the first time in almost 50 years, the FDA reviewed its policies on asbestos testing in products that contain talc, according to Reuters, with recent data from the federal agency showing trace amounts of the known carcinogen in several products. Again at the center of this often controversial debate is Johnson & Johnson, which has defended the safety of its products for years, despite reports dating as far back as the 1970s showing “rather high” levels of the carcinogen in its talc and a recent JAMA study showing no cancer link. Advocates, meanwhile, want stricter safety regulations for the largely unregulated cosmetic talc industry and are calling for warning labels on talc products.
The results of a recent study show that polypharmacy use is more common among HIV-positive adults aged 65 or older compared with those younger than 65, according to Infectious Disease Advisor. With innovations in antiretroviral therapy helping to transform the disease into a more manageable chronic condition and enabling HIV-positive patients to live longer, these older individuals are developing more age-related conditions that they need to manage with other medications. All of this increases the possibility of drug-drug interactions from classes that include benzodiazepines and hypnotics. The researchers stress the need for continuous education and medicine review to reduce risk for this vulnerable population.
On the heals of the coronavirus being declared a public health emergency, the FDA has issued an emergency use authorization for the CDC’s 2019-nCoV Real-Time RT-PCR Diagnostic Panel, according to a press release from the agency. This tool was previously restricted to CDC laboratories only. With the number of new cases seeming to increase every day from this sometimes deadly respiratory infection, this test uses nasal or oral swabs to detect possible infection with 2019-nCoV. The FDA recommends that negative results should be confirmed with healthcare providers.
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More
2 Commerce Drive
Cranbury, NJ 08512